Summary
GlobalData's report, "HIV/AIDS-Pipeline Assessment and Market Forecasts to 2016" provides an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was worth $12 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% for the next seven years to reach $13.7 billion by 2016. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has however succeeded in achieving near zero levels of HIV in infected people. Increased uptake of HAART and increasing awareness (which leads to increased treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 261 molecules currently in development for various disease segments.

Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 HIV/AIDS Market: Market Characterization 6
2.1 Introduction 6
2.2 Disease Overview 6
2.3 HIV/AIDS Market Size 7
2.4 HIV/AIDS Market Forecast and CAGR 8
2.5 Drivers and Barriers for the HIV/AIDS Market 9
2.5.1 Drivers for the HIV/AIDS Market 10
2.5.2 Barriers for the HIV/AIDS Market 12
2.6 Opportunity and Unmet Need 13
2.7 Key Takeaway 16
3 HIV/AIDS Market: Competitive Assessment 17
3.1 Overview 17
3.2 Strategic Competitor Assessment 17
3.3 Product Profiles of the Major Marketed Products in the HIV/AIDS Market 17
3.3.1 Truvada (emtricitabine/tenofovir disoproxil fumarate) 17
3.3.2 Atripla (Efavirenz, Emtricitabine, and Tenofovir) 19
3.3.3 Kaletra (Lopinavir/Ritonavir) 20
3.3.4 Reyataz (Atazanavir sulfate) 21
3.3.5 Sustiva (Efavirenz) 22
3.4 Key Takeaway 24
4 HIV/AIDS Market: Pipeline Assessment 25
4.1 Overview 25
4.2 Strategic Pipeline Assessment 25
4.2.1 Technology Trends Analytic Framework 25
4.3 HIV/AIDS Therapeutics-Promising Drugs under Clinical Development 27
4.4 Molecule Profile for Promising Drugs under Clinical Development 28
4.4.1 Rilpivirine hydrochloride (TMC278) 28
4.4.2 Elvitegravir 29
4.4.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) 29
4.4.4 Racivir 31
4.4.5 Apricitabine (ATC) 31
4.4.6 Tesamorelin 32
4.5 HIV/AIDS Therapeutics Market-Clinical Pipeline by Mechanism of Action 33
4.6 HIV/AIDS Pipeline-Major Different Classes of Drugs Description 34
4.6.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 34
4.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 34
4.6.3 Protease Inhibitors (PIs) 34
4.6.4 Viral Fusion (or Entry) Inhibitors 34
4.6.5 HIV Integrase Strand Transfer Inhibitors 34
4.6.6 Multi-class Combination Products 34
4.6.7 CCR5 Receptor Antagonist 35
4.7 HIV/AIDS Pipeline-Pipeline by Clinical Phases of Development 36
4.7.1 HIV/AIDS Therapeutics-Phase III Clinical Pipeline 36
4.7.2 HIV/AIDS Therapeutics-Phase II Clinical Pipeline 38
4.7.3 HIV/AIDS Therapeutics-Phase I Clinical Pipeline 40
4.7.4 HIV/AIDS Therapeutics-Preclinical Pipeline 42
4.7.5 HIV/AIDS Therapeutics-Early Development Pipeline 44
4.7.6 Discontinued/Suspended Drugs for HIV/AIDS 45
4.8 Key Takeaway 46
5 HIV/AIDS Market: Implications for Future Market Competition 47
6 HIV/AIDS Market: Future Players in the HIV/AIDS Market 49
6.1 Introduction 49
6.2 Gilead Sciences, Inc 49
6.2.1 Company Overview 49
6.2.2 Financial Performance 49
6.2.3 Business Description 49
6.2.4 Viral Infections Portfolio 50
6.2.5 HIV/AIDS Portfolio 51
6.3 Tibotec Pharmaceuticals Ltd 53
6.3.1 Company Overview 53
6.3.2 Viral Infections Portfolio 53
6.3.3 HIV/AIDS Product Portfolio 54
6.4 Avexa Limited 55
6.4.1 Company Overview 55
6.4.2 Financial Performance 55
6.4.3 Business Description 55
6.4.4 Viral Infections Portfolio 56
6.4.5 HIV/AIDS Product Portfolio 56
6.5 Pharmasset, Inc 57
6.5.1 Company Overview 57
6.5.2 Financial Performance 57
6.5.3 Viral Infections Portfolio 57
6.5.4 HIV/AIDS Product Portfolio 57
6.6 Achillion Pharmaceuticals, Inc 58
6.6.1 Company Overview 58
6.6.2 Financial Performance 58
6.6.3 Business Overview 58
6.6.4 Viral Infections Portfolio 59
6.6.5 HIV/AIDS Product Portfolio 59
6.7 Incyte Corporation 60
6.7.1 Company Overview 60
6.7.2 Financial Performance 60
6.7.3 Business Description 60
6.7.4 Viral Infections Portfolio 61
6.7.5 HIV/AIDS Product Portfolio 61
6.8 Myriad Pharmaceuticals, Inc 61
6.8.1 Company Overview 61
6.8.2 Financial Performance 61
6.8.3 HIV Portfolio 61
6.8.4 HIV/AIDS Product Portfolio 61
7 HIV/AIDS Market: Appendix 62
7.1 Market Definition 62
7.2 Abbreviations 62
7.3 Research Methodology 64
7.3.1 Coverage 64
7.3.2 Secondary Research 65
7.3.3 Forecasting 65
7.3.4 Primary Research 68
7.3.5 Expert Panels 68
7.4 Contact Us 68
7.5 Disclaimer 68
7.6 Sources 69

List of Tables
1.1 List of Tables
Table 1: Global HIV/AIDS Market Forecast, 2001-2009 8
Table 2: Global HIV/AIDS Market Forecast, 2009-2016 9
Table 3: HIV Therapeutics Market, Key Drug Going Off Patent, 2009-2016 13
Table 4: Marketed Product Analysis in the HIV/AIDS Market, 2010 23
Table 5: HIV/AIDS Therapeutics-Most Promising Drugs under Clinical Development, 2010 27
Table 6: HIV Market, Different Classes of Approved Drugs 35
Table 7: HIV/AIDS Pipeline, Phase III, 2010 36
Table 8: HIV/AIDS Pipeline, Phase II, 2010 38
Table 9: HIV/AIDS Pipeline, Phase I, 2010 40
Table 10: HIV/AIDS Pipeline, Preclinical, 2010 42
Table 11: HIV/AIDS Pipeline, Early Development, 2010 44
Table 12: List of Discontinued Drugs for HIV/AIDS, 2010 45
Table 13: Gilead Sciences-Viral Infections Pipeline, 2010 50
Table 14: Tibotec Pharmaceuticals Ltd-Viral Infections Pipeline, 2010 53
Table 15: Avexa Ltd-Viral Infections Pipeline, 2010 56
Table 16: Pharmasset, Inc-Viral Infections Pipeline, 2010 57
Table 17: Achillion Pharmaceuticals, Inc-Viral Infections Pipeline, 2010 59
Table 18: Incyte Corporation-Viral Infections Pipeline, 2010 61

List of Figures
1.2 List of Figures
Figure 1:  Global HIV/AIDS Market Forecast, 2001-2009 8
Figure 2:  Global HIV/AIDS Market Forecast, 2009-2016 9
Figure 3:  Opportunity and Unmet Need in the HIV/AIDS Market, 2010 15
Figure 4:  Strategic Competitor Assessment of the Marketed Products for HIV/AIDS, 2010 17
Figure 5:  Technology Trends Analytic Framework of the HIV/AIDS Pipeline, 2010 26
Figure 6:  Technology Trends Analytic Framework of the HIV/AIDS Pipeline-Description, 2010 26
Figure 7:  HIV/AIDS Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 33
Figure 8:  HIV/AIDS Pipeline by Phase of Clinical Development, 2010 36
Figure 9:  Implications for Future Market Competition in the HIV/AIDS Market, 2010 47
Figure 10: HIV/AIDS Therapeutics Market-Clinical Pipeline by Company, 2010 49
Figure 11: GlobalData Methodology 64
Figure 12: GlobalData Market Forecasting Model 67
Table 19: Myriad Pharmaceuticals, Inc-HIV Pipeline, 2010 61